Terms: = Prostate cancer AND NCOA4, RP11-481A12_4, 8031, ENSG00000138293, PTC3, ELE1, Q13772, RFG, DKFZp762E1112, ARA70 AND Treatment
15824 results:
1. Incretin-based drugs decrease the incidence of prostate cancer in type 2 diabetics: A pooling-up analysis.
Lin Y; Xu G; Li L; Xiang J; Zhai L
Medicine (Baltimore); 2024 May; 103(20):e38018. PubMed ID: 38758855
[TBL] [Abstract] [Full Text] [Related]
2. A bicentric retrospective study of the correlation of EAU BCR risk groups with
Poterszman N; Merlin C; Margail C; Ouvrard E; Imperiale A; Somme F
Sci Rep; 2024 May; 14(1):10908. PubMed ID: 38740809
[TBL] [Abstract] [Full Text] [Related]
3. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract] [Full Text] [Related]
4. Active surveillance of low-grade prostate cancer using the SurACaP Criteria: A multi-institutional series with a median follow-up of 10years.
Leclercq L; Bastide C; Lechevallier E; Walz J; Charvet AL; Gondran-Tellier B; Campagna J; Savoie PH; Long-Depaquit T; Daniel L; Rossi D; Pignot G; Baboudjian M
Fr J Urol; 2024 Mar; 34(2):102571. PubMed ID: 38717459
[TBL] [Abstract] [Full Text] [Related]
5. Cinobufotalin Capsule Combined with Zoledronic Acid in the treatment of Pain Symptoms and Clinical Efficacy in prostate cancer Patients with Bone Metastases: A Retrospective Study.
Zhang F; Dong Y; Chen F; Niu M; Liu Z; Wang C
Arch Esp Urol; 2024 Apr; 77(3):242-248. PubMed ID: 38715164
[TBL] [Abstract] [Full Text] [Related]
6. Identifying risk factors for hypoxemia during emergence from anesthesia in patients undergoing robot-assisted laparoscopic radical prostatectomy.
Zhang Q; Zhu L; Yuan S; Lu S; Zhang X
J Robot Surg; 2024 May; 18(1):200. PubMed ID: 38713381
[TBL] [Abstract] [Full Text] [Related]
7. Impact of COVID-19 on the time to counseling and treatment of prostate cancer.
Filipas DK; Pose RM; Marks P; Tennstedt P; Beyer B; Tilki D; Isbarn H; Maurer T; Ludwig TA; Heinzer H; Steuber T
Aging Male; 2024 Dec; 27(1):2347465. PubMed ID: 38712892
[TBL] [Abstract] [Full Text] [Related]
8. A mitochondrion-targeted cyanine agent for NIR-II fluorescence-guided surgery combined with intraoperative photothermal therapy to reduce prostate cancer recurrence.
Liu C; Chang Z; Chen K; Xue Q; Shu B; Wei Z; Zhou X; Guo L; Zhang Y; Pan Y; Cao Q; Liang H; Sun Q; Zhang X
J Nanobiotechnology; 2024 May; 22(1):224. PubMed ID: 38702709
[TBL] [Abstract] [Full Text] [Related]
9. Survival benefit of radical prostatectomy in patients with advanced TURP-diagnosed prostate cancer: a population-based real-world study.
Lin D; Lin L; Ye L; Li T; Wei Y; Li L
BMC Surg; 2024 May; 24(1):134. PubMed ID: 38702689
[TBL] [Abstract] [Full Text] [Related]
10. The effect of a fermented soy beverage among patients with localized prostate cancer prior to radical prostatectomy.
Lokeshwar SD; Ali A; Weiss TR; Reynolds J; Shuch BM; Ferencz T; Kyriakides TC; Mehal WZ; Brito J; Renzulli J; Leapman MS
BMC Urol; 2024 May; 24(1):102. PubMed ID: 38702664
[TBL] [Abstract] [Full Text] [Related]
11. On the necessity of specialized knowledge-based models for SBRT prostate treatments plans.
Scaggion A; Cavinato S; Dusi F; El Khouzai B; Guida F; Paronetto C; Rossato MA; Sapignoli S; Scott ASA; Sepulcri M; Paiusco M
Phys Med; 2024 May; 121():103364. PubMed ID: 38701626
[TBL] [Abstract] [Full Text] [Related]
12. MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Syc-Mazurek SB; Zhao-Fleming H; Guo Y; Tisavipat N; Chen JJ; Zekeridou A; Kournoutas I; Orme JJ; Block MS; Lucchinetti CF; Mustafa R; Flanagan EP
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200249. PubMed ID: 38696737
[TBL] [Abstract] [Full Text] [Related]
13. treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
Mathew Thomas V; Jo Y; Tripathi N; Roy S; Chigarira B; Narang A; Gebrael G; Hage Chehade C; Sayegh N; Galarza Fortuna G; Ji R; Campbell P; Li H; Agarwal N; Gupta S; Swami U
JAMA Netw Open; 2024 May; 7(5):e249417. PubMed ID: 38696168
[TBL] [Abstract] [Full Text] [Related]
14. Dual-mode fluorescence and colorimetric smartphone-based sensing platform with oxidation-induced self-assembled nanoflowers for sarcosine detection.
Liu P; Sun Q; Gai Z; Yang F; Yang Y
Anal Chim Acta; 2024 Jun; 1306():342586. PubMed ID: 38692787
[TBL] [Abstract] [Full Text] [Related]
15. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance-Guided Radiotherapy.
Westerhoff JM; Daamen LA; Christodouleas JP; Blezer ELA; Choudhury A; Westley RL; Erickson BA; Fuller CD; Hafeez S; van der Heide UA; Intven MPW; Kirby AM; Lalondrelle S; Minsky BD; Mook S; Nowee ME; Marijnen CAM; Orrling KM; Sahgal A; Schultz CJ; Faivre-Finn C; Tersteeg RJHA; Tree AC; Tseng CL; Schytte T; Silk DM; Eggert D; Luzzara M; van der Voort van Zyp JRN; Verkooijen HM; Hall WA
JAMA Netw Open; 2024 May; 7(5):e2410819. PubMed ID: 38691356
[TBL] [Abstract] [Full Text] [Related]
16. Identification and Quantification of Radiotherapy-related Protein Expression in cancer Tissues Using the Qupath Software and Prediction of treatment Response.
Hasegawa T; Someya M; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Okuda R; Kaguchi J; Ohguro A; Kamiyama R; Ashina A; Toshima Y; Hirohashi Y; Torigoe T; Sakata KI
In Vivo; 2024; 38(3):1470-1476. PubMed ID: 38688633
[TBL] [Abstract] [Full Text] [Related]
17. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
18. Synthesis and SAR investigation of biphenylaminoquinoline derivatives with benzyloxy substituents as promising anticancer agents.
Wu YC; Lu MT; Kuo SC; Chu PC; Chang CS
Chem Biol Drug Des; 2024 May; 103(5):e14509. PubMed ID: 38684369
[TBL] [Abstract] [Full Text] [Related]
19. Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer.
Thomsen FF; Garmo H; Egevad L; Stattin P; Brasso K
Scand J Urol; 2024 Apr; 59():76-83. PubMed ID: 38682731
[TBL] [Abstract] [Full Text] [Related]
20. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract] [Full Text] [Related]
[Next]
